相关实验视频

Updated: Jul 28, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

库尔库增加了耐辐射鼻癌的辐射敏感性

Guoyu Wang¹, Jie Zhu², Zengxian Wang¹

¹Department of Radiology, Taizhou Central Hospital, Taizhou University Hospital, 318000 Taizhou, Zhejiang, China.

Discovery medicine

|June 5, 2023

概括

黄素有效地通过抑制扩散和侵袭来对抗抗辐射性鼻癌 (NPC),同时促进细胞亡和增强辐射敏感性. 这通过调节miR-205-5p和TP53INP1表达而发生,提供了潜在的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
辐射疗法辐射疗法

背景情况:

鼻癌 (NPC) 是一种具有挑战性的癌症,像C6661-IR这样的耐辐射菌株构成了重要的治疗障碍.
了解放射电阻背后的分子机制对于开发有效的治疗策略至关重要.

研究的目的:

为了研究黄素对抗辐射NPC (C6661-IR) 细胞的增殖,侵入,亡和辐射敏感性的影响.
阐明涉及miR-205-5p和TP53INP1.1.的潜在辐射敏感化机制.

主要方法:

通过持续照射诱导耐辐射NPC细胞系.
用克隆形成,MTT,流细胞计和Transwell等测试评估黄素对辐射敏感性,扩散,亡和入侵的影响.
分析关键蛋白质和microRNA表达 (Bax,Bcl-2,分裂-caspase 3,miR-205-5p,TP53INP1) 通过西方抹黑和RT-qPCR.

主要成果:

黄素显著抑制了C6661-IR细胞的扩散和入侵,促进了细胞灭绝,并增强了C6661-IR细胞的放射敏感性.
黄素治疗导致miR-205-5p水平降低,TP53INP1表达增加.
miR-205-5p被确定为TP53INP1的直接向分子,其调制影响了黄素的生物影响.

结论:

黄素通过增强辐射敏感性和减少瘤细胞的攻击性,对抗放射性NPC表现出强大的抗癌作用.
该机制涉及miR-205-5p的下调和TP53INP1的上调,突出了miR-205-5p/TP53INP1轴作为一个关键的调解器.
黄素代表了一种有前途的治疗剂,可以在鼻癌中克服放射电阻.

关键词:

在TP53INP1中使用.库尔库明是一种黄素.在 miR-205-5p 中.具有耐辐射的NPC菌株.辐射敏感化辐射敏感化

更多相关视频

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...